PolyPid Ltd. Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results

100 Patient s Enrolled into Phase 3 SHIELD I and SHIELD II Trial s of D-PLEX 100 in Abdominal Surgery Recently Initiated Phase 3 SHIELD II Trial Granted Breakthrough Therapy Designation from FDA for D-PLEX 100 for Prevention of SSIs in P atients U ndergoing E lective C olorectal S urgery